Clare Wareing
CEO & Founder
Cumulus Oncology
The startup develops a selective oral Chk1 kinase inhibitor that enhances DNA repair mechanisms in cancer cells. This therapy aims to improve treatment efficacy and patient outcomes in oncology by targeting a critical pathway in cancer progression.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$69.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Oncology drug development faces persistently high failure rates in late-stage clinical trials, resulting in significant sunk costs and delayed access to improved cancer therapies. Identifying and prioritizing assets with the highest potential for clinical success early in the development process remains a challenge.
Solution
Cumulus Oncology operates as an oncology biotech creation company, identifying promising oncology assets and accelerating their development through a "one team – multiple companies/projects" approach. Cumulus leverages scientific expertise, seed capital, and a network of partners to create and build spin-out companies focused on specific therapeutic targets or modalities. By strategically distributing efforts across multiple companies, Cumulus aims to increase the chances of successful outcomes and deliver patient benefit and shareholder value. Cumulus actively seeks new targets, assets, and technology platforms with the potential to become oncology therapeutics.
Target Audience
Cumulus Oncology targets asset holders from academic and commercial backgrounds, including universities, drug discovery groups, biotech companies, and pharma companies seeking to re-prioritize their oncology portfolios.
Features
- Robust asset curation engine for identifying promising oncology opportunities
- Allocation of seed capital to support early-stage development
- Experienced drug discovery team members providing biotech management expertise
- "One team
- multiple companies/projects" approach for efficient resource deployment
- Partnerships with platform technology companies to enhance access to new targets
- Bespoke validation experiments to de-risk opportunities
- In-house data science and bioinformatics capabilities to enhance decision-making
- Portfolio approach to reduce risk across multiple technologies and modalities